|View printer-friendly version|
|Quidel Announces Promotion of Scot M. McLeod to Senior Vice President, Operations|
SAN DIEGO--(BUSINESS WIRE)--June 26, 2007--Quidel Corporation (NASDAQ:QDEL), a leading provider of rapid point-of-care diagnostic tests, announced today that Scot M. McLeod, currently vice president, operations, has been promoted to senior vice president, operations, effective July 2, 2007.
"We are pleased to recognize Scot's demonstrated leadership and success by naming him senior vice president, operations. Under his leadership, the Company has achieved significant manufacturing efficiencies through automation, process characterization and supply chain development. Scot and his team have engineered and customized Quidel's production capabilities to a performance and quality competitive advantage aiding in market leadership in several test categories. Scot's promotion is well deserved," said Caren Mason, the Company's president and chief executive officer.
Scot M. McLeod has been an integral part of the Company's operations team for almost 10 years and has served as vice president, operations for the Company since 2001, having responsibility for the performance of the San Diego manufacturing facility.
Mr. McLeod has more than 20 years experience in high volume manufacturing operations. Prior to joining the Company as director of production in 1997, Mr. McLeod had worked at Medtronic Inc. and Hybritech in engineering and project leadership roles. Mr. McLeod has a Bachelor of Science degree in Chemical Engineering from the University of New Hampshire.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well being of people around the globe through the discovery, development, manufacturing and marketing of rapid diagnostic solutions at the point of care (POC) in infectious diseases and reproductive health. Marketed under the leading brand name of QuickVue(R), Quidel's portfolio of products currently includes tests that aid in the diagnosis of several disease or condition states, including influenza, respiratory syncytial virus, Fecal Occult Blood, Strep A, pregnancy, bacterial vaginosis, H. pylori and Chlamydia. Quidel's products are sold to healthcare professionals with a focus on the physician office lab and acute care markets through leading medical distribution partners on a worldwide basis. Quidel's Specialty Products Group (SPG) develops research products in the fields of oncology and bone health with potential future point-of-care applications. By building value in rapid diagnostic tests, Quidel provides leadership to the industry and among healthcare professionals allowing for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit. For more information, visit www.quidel.com, www.colorectal-test.com or www.flutest.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation, seasonality, the length and severity of cold and flu seasons, uncertainty surrounding the detection of novel influenza viruses involving human specimens, adverse changes in the competitive and economic conditions in domestic and international markets, actions of our major distributors, technological changes and uncertainty with research and technology development, including any future molecular-based technology, the reimbursement system currently in place and future changes to that system, manufacturing and production delays or difficulties, adverse actions or delays in product reviews by the U.S. Food and Drug Administration (the "FDA"), intellectual property, product liability, environmental or other litigation, required patent license fee payments not currently reflected in our costs, potential inadequacy of booked reserves and possible impairment of goodwill, and lower than anticipated sales or market penetration of our new products. Forward-looking statements typically are identified by the use of terms such as "may," "will," "should," "might," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. The risks described under "Risk Factors" in reports and registration statements that we file with the SEC from time to time should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date of this press release. We undertake no obligation to publicly release the results of any revision or update of the forward-looking statements.